Table 3: Sentinel lymph node positivity in patients diagnosed with pure ductal carcinoma in situ (DCIS) determined by hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC).

InstitutionNo. of patients ( 𝑛 ) Sentinel lymph node positivity in pure DCIS: by H&E or (IHC)

European Institute of Oncology, Milan [3]8541.9%
University of Padova, Italy [4]1021%
Lee Moffitt Cancer Center, FL, USA [5]19513%: 6.5% by H&E; 6.5% by IHC
Lee Moffitt Cancer Center, FL, USA [6]5595%: 1.5% by H&E, 3.5% by IHC
University of Paris, France [7]1106%
Sibley Memorial Hospital, Washington DC, USA [8]1107.2%: 3.6% by H&E; 3.6% by IHC
Memorial Sloan Kettering Cancer Center [9]7612%
Acibadem University, Faculty of Medicine, Istanbul (present study)405%: 2.5% by H&E, 2.5% by IHC